title: Expression of a marker for colonic crypt base cells is correlated with poor prognosis in human colorectal cancer.
abstract: BACKGROUND
  There is a need for markers in colorectal cancer which will allow subclassification of stage groups into subgroups with high versus low risk of recurrent disease.
  
  
  OBJECTIVE
  To develop monoclonal antibodies that recognise antigens or immature crypt base cells, on the assumption that in a neoplasm undifferentiated but not the terminally differentiated cells will be responsible for tumour progression.
  
  
  METHODS
  Colon crypt cells which were isolated from human colonic mucosa by EDTA/EGTA incubation were studied. By stepwise harvesting, crypt base cell enriched fractions were obtained, and after incubation with antibodies against dominant antigens, used as immunogens.
  
  
  RESULTS
  Of one crypt base cell specific antibody (5E9), the reactive epitope appeared to be a non-terminal carbohydrate in the mucin O-glycans of the colon. The epitope did not seem to be colon specific, but was expressed in a variety of other tissues. In colorectal carcinomas, 5E9 immunoreactivity identified a subgroup of patients with a tendency for worse prognosis.
  
  
  CONCLUSIONS
  A mucin associated maturation epitope was identified in colonic crypt base cells, the expression of which in Dukes' stage B3 colorectal carcinoma may be associated with poor prognosis.
authors.affiliation: Department of Pathology, Maastricht University Hospital, The Netherlands.
authors.forename: A A
authors.initials: AA
authors.lastname: van der Wurff
authors.forename: J
authors.initials: J
authors.lastname: ten Kate
authors.forename: P T
authors.initials: PT
authors.lastname: Marx
authors.forename: E P
authors.initials: EP
authors.lastname: van der Linden
authors.forename: C C
authors.initials: CC
authors.lastname: Beek
authors.forename: F J
authors.initials: FJ
authors.lastname: Bovelander
authors.forename: J
authors.initials: J
authors.lastname: Dekker
authors.forename: W N
authors.initials: WN
authors.lastname: Dinjens
authors.forename: M F
authors.initials: MF
authors.lastname: von Meyenfeldt
authors.forename: J W
authors.initials: JW
authors.lastname: Arends
authors.forename: F T
authors.initials: FT
authors.lastname: Bosman
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis*; D002455:Cell Division / Q000276:immunology; D002584:Cervix Uteri / Q000737:chemistry; D003106:Colon / Q000737:chemistry; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology*; D000939:Epitopes / Q000032:analysis* / Q000737:chemistry / Q000276:immunology; D005260:Female; D005704:Gallbladder / Q000737:chemistry; D006801:Humans; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000737:chemistry; D007422:Intestines / Q000473:pathology; D008297:Male; D008679:Metaplasia / Q000378:metabolism; D016253:Microscopy, Immunoelectron; D008875:Middle Aged; D055262:Mucin-2; D009077:Mucins / Q000276:immunology*; D009367:Neoplasm Staging; D010179:Pancreas / Q000737:chemistry; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D000939:Epitopes; C524625:MUC2 protein, human; D055262:Mucin-2; D009077:Mucins